Latest News

FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC
FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC

June 23rd 2025

FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated patients.

Pembrolizumab and Chemoradiation Deliver Durable Responses in Stage III NSCLC
Pembrolizumab and Chemoradiation Deliver Durable Responses in Stage III NSCLC

June 21st 2025

Savolitinib Plus Osimertinib Elicits Durable Responses in MET+ Advanced NSCLC
Savolitinib Plus Osimertinib Elicits Durable Responses in MET+ Advanced NSCLC

June 20th 2025

Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC

June 19th 2025

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights
Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

June 19th 2025

Video Series
Video Interviews
Podcasts

More News